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Abstract
All the Italian Centres in charge of screening, diagnosis, and follow-up of infants with congenital
hypothyroidism participate in the Italian National Registry of affected infants, which performs the
nationwide surveillance of the disease. It was established in 1987 as a program of the Health
Ministry and is coordinated by the Istituto Superiore di Sanità. The early diagnosis performed by
the nationwide newborn screening programme, the prompt treatment and the appropriate clinical
management of the patients carried out by the Follow-up Centres, and the surveillance of the
disease performed by the National Register of infants with congenital hypothyroidism are the
components of an integrated approach to the disease which has been successfully established in our
country.
The aim of the Register is to monitor efficiency and effectiveness of neonatal screening, to provide
disease surveillance and to allow identification of possible aetiological risk factors for the disease.
During the past twenty years the active and continuous collaboration between the Register and the
Italian Screening and Follow up Centres for Congenital Hypothyroidism allowed to perform a
standardization of screening procedures and considerable improvements in the time at starting
treatment and in the dose of therapy. Furthermore, the large amount and the high quality of
information collected in the Register provided a unique opportunity for research into the disease.
This because data collected in the Register are highly representative as referred to the entire Italian
population with congenital hypothyroidism. The results derived from the epidemiological studies
performed in these years, by using the Register database, contributed to deepen the knowledge of
congenital hypothyroidism, to start identifying the most important risk factors for the disease, and
to orient molecular studies aimed at identifying new genes involved in the aetiology of this
condition.
Introduction
The main objective of neonatal screening, the eradication
of mental retardation after congenital hypothyroidism
(CH), has been achieved in all the countries where nation-
wide screening programmes have been established [1-3].
In Italy the nationwide newborn screening programme for
CH began in 1977 as a pilot program in 7 laboratories and
then progressively developed all over the country. The
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100% coverage of neonatal population has been achieved
since the 90's thanks to an efficient network of 26 regional
and inter-regional Screening and Follow-up Centres active
in our country. At present in all the Italian Screening Cent-
ers a biochemical assessment of TSH, and in 11 of the 26
centres also of T4, is performed on dried spot blood
within a few days from birth. In all the Centers positive
results of screening tests are confirmed by definitive tests
of thyroid function on serum. These include TSH, free T4
(FT4) and/or T4. Thyroid ultrasound and/or scintigraphy
are generally performed to complete the CH diagnosis.
Infants with confirmed primary CH are then referred to
the Follow-up Center of their own region for starting
replacement therapy. According to international guide-
lines [1,4,5], when the definitive diagnosis is not estab-
lished in the neonatal period and a suspicion of transient
primary hypothyroidism is present, a reevaluation of diag-
nosis is performed at the age of 3 years after a withdrawal
of the replacement therapy to ascertain the persistence of
CH. At that time, serum T4, FT4, and TSH levels are meas-
ured, and ultrasound imaging, scintigraphy, and clinical
evaluation are performed to establish the definitive diag-
nosis.
All the Italian Centres in charge of screening, diagnosis
and follow-up of infants with CH participate in the Italian
National Register of Infants with Congenital Hypothy-
roidism (INRICH), which performs the nationwide sur-
veillance of the disease. The INRICH was established in
1987 as a program of the Health Ministry [6] and is coor-
dinated by the Istituto Superiore di Sanità. The aim of the
INRICH is to monitor efficiency and effectiveness of neo-
natal screening, to provide disease surveillance and to
allow identification of possible aetiological risk factors for
CH. Information on new cases with CH are collected in
the INRICH by means 3 questionnaires filled in at diagno-
sis. These include anonymous data concerning CH infants
such as screening and confirmatory laboratory tests, infor-
mation on demographic data, details on clinical state in
neonatal period, diagnostic investigations (biochemical
determinations, radiography of the knee, thyroid scintig-
raphy, and ultrasound), information regarding preg-
nancy, birth, and family background, starting and dose of
the replacement therapy. It is important to note that
babies with transient hyperthyrotropinemia on the basis
of spontaneous normalization of TSH between screening
and diagnosis are not recorded in the Register. Since 1991,
the INRICH started collecting specific data on the occur-
rence of congenital anomalies (detected during neonatal
period) other than those of the thyroid gland by using a
specific reporting form. The Screening Centres are respon-
sible for collecting information in the questionnaires and
for the accuracy of their compilation. Data are coded and
stored in an informed database at the Istituto Superiore di
Sanità and results of the Register are reported in a web site
http://www.iss.it/rnic/, presented yearly in a national con-
ference, and published in international scientific journals.
Discussion
During the past twenty years the active and continuous
collaboration between the INRICH and the Italian Screen-
ing and Follow up Centres allowed to perform a standard-
ization of screening procedures and considerable
improvements in the time at starting treatment and in the
dose of therapy. In fact, while the median value of infant's
age at starting therapy was 23 days between 1987 and
1999, the last analysis of the INRICH data (performed on
data referred to babies born between 2000 and 2004) con-
firmed a reduction of this value (19 days) with significant
differences among the 3 diagnoses: agenesia 16 days; ecto-
pia: 15 days; in situ thyroid: 23 days. Similar improve-
ments have been also obtained in dose of L-T4 at starting
therapy. The median value of L-T4 dose was 8.0 μg/Kg/day
between 1987 and 1999, and 9.6 μg/Kg/day between
2000 and 2004. An analysis on data referring to 2005–
2008 is going on and the results are expected further
improved.
The INRICH has also allowed to well characterize the Ital-
ian population of babies with CH. As expected, in Italy the
frequency of the disease is higher in female than in male
babies with a F/M sex ratio = 1.7. However, when thyroid
disgenesis is considered separately from in situ thyroid,
the sex ratio results: F/M = 2.0 among babies with thyroid
disgenesis and F/M = 1.0 among those with in situ thyroid.
Moreover, the INRICH data have shown that scintigraphy
and/or ultrasonography is performed in the 64% of CH
babies before starting therapy and that the different diag-
noses are distributed as follows among babies with per-
manent CH: 40% ectopy, 26% agenesis, 34% in situ
thyroid http://www.iss.it/rnic/.
The high number of CH infants with confirmed diagnosis
recorded in the INRICH (about 3800 at the end of 2007)
and the fact that the INRICH is a population-based regis-
ter have allowed to perform a robust estimation of the CH
incidence in our country. This results to be 1:2400 live
borns (1995–2003). It is important to note that this esti-
mation is based only on cases with permanent forms of
CH. In fact, all the cases with transient hypothyroidism,
ascertained by means a re-evaluation of the diagnosis after
a withdrawal of the replacement therapy at 3 years of age,
are not considered in the incidence estimation. Moreover,
to avoid the possibility of including some cases with tran-
sient hypothyroidism not re-evaluated yet, only data
regarding children older than 3 years at the time of analy-
sis are used. This methodology avoids the danger of draw-
ing conclusions from an overestimation of the CH
incidence and allows to ascertain the real impact of this
condition on the Italian newborn population. On thisItalian Journal of Pediatrics 2009, 35:2 http://www.ijponline.net/content/35/1/2
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regard, the INRICH data have also shown a high fre-
quency of twins in the CH population with a proportion
3-fold higher in the CH population (3.5%) than in the
Italian general population (1.1%) [7,8]. For the first time
the INRICH data have allowed to estimate the CH inci-
dence in multiple and single deliveries separately. It was
found 3-fold higher in multiple (10.1 per 10,000 live
births) than in single deliveries (3.2 per 10,000 live
births) with a relative risk of CH occurrence in twin deliv-
eries of 3.1 (95% CI, 2.5–3.9) [7]. Moreover, the analysis
of re-evaluated infants with high suspicion of transient
hypothyroidism recorded in the INRICH has shown a
twin prevalence of 1.9% among infants who were affected
by permanent CH and 13.2% in those who resulted
affected by transient CH. Taken together these findings
have demonstrated an increased risk for both permanent
and transient CH in multiple than in single deliveries.
This increased CH risk in multiple pregnancies has impor-
tant implications in terms of public health given the high
number of induced pregnancies, in Italy as well as in other
Western countries, because of the increasing use of tech-
niques of assisted reproduction and drugs inducing ovula-
tion [9,10].
It is important to underline that, beside an efficient
nationwide surveillance of the disease, the large amount
and the high quality of information collected in the
INRICH during these twenty years provided a unique
opportunity for research into this condition. This because
data collected in the INRICH are highly representative as
referred to the entire Italian population of infants with
CH. One of the most important results concerns the well
known association between congenital malformations
and CH [11]. Given the large CH population recorded in
the INRICH, it has been possible to study a high number
of CH infants with extrathyroidal malformations and
compare these data with those of the International Clear-
inghouse for Birth Defects, the worldwide database col-
lecting information on infants born with congenital
malformations [12]. By using this approach, it has been
possible to demonstrate that not all congenital extrathy-
roidal malformations but only anomalies of heart, nerv-
ous system, eyes (representing precocious structures in the
developing embryo) and multiple congenital malforma-
tions are significantly associated to CH [13]. These find-
ings have strongly suggested a very early impairment in
the first stages of embryo development with a consequent
involvement of different organs and structures. For what
specifically concerns cardiac congenital malformations,
the comparison of the INRICH data with other national
and/or regional registries of congenital malformations
included in the database of the International Clearing-
house for Birth Defects, have demonstrated that the most
frequent cardiac malformations in the CH population
were represented by the atrial septal defects with a rate of
13.8 of 1000 [10]. This finding is different from what
found in the general population in which the most fre-
quent cardiac anomalies (3 of 1000) are represented by
ventricular septal defects [14]. These peculiar results ori-
ented molecular biologists to focus their investigations on
genes involved in both heart and thyroid development.
Therefore, as many point mutations have had identified
in NKX2.5 trascription factor in families with atrial septal
defects [15], the possible involvement of NKX2.5 muta-
tions in thyroid disgenesis was investigated both in vivo
model and humans. It was found that mutations in this
gene can contribute to thyroid disgenesis phenotype [16].
It has been demonstrated that CH is a multigenic disease
[17-20]. However, the occurrence of mutations in genes
known to be involved in the development of the disease
have been observed only in a small proportion of the CH
patients. Moreover, the aetiological role of specific envi-
ronmental risk factors has not completely elucidated yet.
These considerations imply that the etiology of CH is still
largely unknown and that further efforts to identify new
genetic markers and modifiable (environmental) risk fac-
tors are needed to allow an efficient primary prevention of
the disease. To this end a population-based case control
study was carried out to identify the most important risk
factors for permanent and transient forms of CH on the
basis of information collected in the INRICH question-
naires [21]. This study showed that many risk factors con-
tribute to the aetiology of CH suggesting a multifactorial
origin of the disease in which genetic and environmental
(especially iodine deficiency and maternal diabetes) risk
factors play a role in the development of the disease. The
multifactorial origin of CH was also supported by results
obtained in the above mentioned study on CH twins
recorded in the INRICH between 1989 and 2000 [7]. This
study showed that, despite a low concordance rate (4.3%)
for permanent CH observed among twins at birth, a high
recurrence risk for the disease was present among siblings
of CH cases (Sibling Recurrence Risk = 35.4; 95%CI: 4.7 –
269.3). These findings strongly suggested the occurrence
of non-inheritable postzygotic events in the aetiology of
CH and that environmental risk factors may act as a trigger
on a susceptible genetic background in the aetiology of
the disease.
Conclusion
The surveillance of CH carried out by the INRICH together
with the early diagnosis made by the nationwide screen-
ing programme, the prompt treatment and the appropri-
ate clinical management of the patients performed by the
Italian Follow-up Centres for CH, are elements of an inte-
grated approach to CH which has been successfully estab-
lished in our country. However, despite the important
results obtained in terms of standardization of screening
procedures and improvements in time and dose at startingItalian Journal of Pediatrics 2009, 35:2 http://www.ijponline.net/content/35/1/2
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treatment, we are conscious that further efforts have to be
made to improve the diagnosis of CH and to make more
precocious the therapy establishment in all affected
infants. To this end national recommendations on diag-
nosis and follow-up of CH, resulting from the integration
of available guidelines [1,5,22], the Italian Screening and
Follow-up Centres experience, and information derived
from the INRICH surveillance activity, are needed. These
would help to carry out a process of harmonization and
optimization of the Italian Screening programme with a
consequent guarantee of an optimal quality of life to all
CH infants.
For what concerns the INRICH research activity, the
results derived from the epidemiological studies per-
formed in these years have contributed to deepen knowl-
edge of CH, to start identifying the most important risk
factors for the disease, and to orient molecular biologists
towards the identification of new genes involved in the
aetiology of the disease. At present, further collaborative
research studies based on the INRICH database are going
on and our efforts in the field of CH risk factors identifi-
cation are continuing with the aim of making possible, in
a near future, an efficient primary prevention of a disease
which still represents the most frequent endocrinopathy
in infancy.
Finally, on the basis of our Italian experience we are con-
fident that, as proposed by other Authors [2], the possible
availability of a central European wide database on CH
would represent a potent tool of surveillance, epidemio-
logical research and knowledge on CH, and that the
INRICH could strongly contribute to achieve this goal.
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